Lifeboat Foundation

LONDON, June 1 (Reuters) — Monkeypox appears to be spreading from person to person in England, the UK Health Security Agency (UKHSA) said on Wednesday.

The usually mild viral disease, which is endemic in west and central Africa, is understood to spread through close contact. Until early May, cases rarely cropped up outside Africa and were typically linked to travel to there.

“The current outbreak is the first time that the virus has been passed from person to person in England where travel links to an endemic country have not been identified,” the agency said.

Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib). Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL).

Updated findings from the UNITY-CLL clinical trial continued to show a possible increased risk of death in patients receiving Ukoniq. As a result, we determined the risks of treatment with Ukoniq outweigh its benefits. Based upon this determination, the drug’s manufacturer, TG Therapeutics, announced it was voluntarily withdrawing Ukoniq from the market for the approved uses in MZL and FL.

Health care professionals should stop prescribing Ukoniq and switch patients to alternative treatments. Inform patients currently taking Ukoniq of the increased risk of death seen in the clinical trial and advise them to stop taking the medicine. In limited circumstances in which a patient may be receiving benefit from Ukoniq, TG Therapeutics plans to make it available under expanded access.

Is it all down to a cup of joe then?

People who drink coffee regularly, with or without sugar, both seem to benefit from the beverage as it cuts down on the risk of early death, * The Guardian* reported.

Grabbing a cup of coffee may just be something you do almost unconsciously as you sit down with your morning newspaper or before you start your workday. As the day wears on, you might be down three cups or maybe even five without giving it a second thought. However, scientists have been very conscious of the world’s coffee consumption.

Continue reading “Coffee drinkers have a 29 percent lower risk of death than non-coffee drinkers” »

In response to a request from the province of British Columbia (BC), from January 31, 2023 to January 31, 2026, adults (18 and over) in BC will not be subject to criminal charges for the possession of up to 2.5 grams of certain illegal drugs for personal use.

The federal Minister of Mental Health and Addictions and Associate Minister of Health granted the province of British Columbia (BC)’s request for a subsection 56 exemption under the Controlled Drugs and Substances Act for adults (18 years of age and older) in the province to possess small amounts of certain illegal drugs for personal use. BC has referred to this as “decriminalization of personal possession of illegal drugs”.

What this means is that from January 31, 2023 to January 31, 2026, adults (18 and over) in BC will not be subject to criminal charges for the possession of a cumulative total of up to 2.5 grams of certain illegal drugs for personal use. Instead, all individuals found in possession of substances listed in the exemption of up to 2.5 grams for personal use will, at minimum, be provided with information on available local health and social services. They can also be provided with assistance to connect with those services if requested. The exemption only covers possession for personal use by adults (18 and over) in BC with no intent to traffic, produce or export.

British Columbia has been greatly impacted by overdose deaths and related harms, and declared the overdose crisis a public health emergency in 2016. As part of the province’s comprehensive public health response, BC requested a subsection 56 exemption under the Controlled Drugs and Substances Act (CDSA) so that adults in the province will not be subject to criminal charges for personal possession of small amounts of certain illegal drugs.

Continue reading “Exemption from Controlled Drugs and Substances Act: Personal possession of small amounts of certain illegal drugs in British Columbia (January 31, 2023 to January 31, 2026)” »

Tomatoes gene-edited to produce vitamin D, the sunshine vitamin, could be a simple and sustainable innovation to address a global health problem.

Researchers used gene editing to turn off a specific molecule in the plant’s genome which increased provitamin D3 in both the fruit and leaves of tomato plants. It was then converted to vitamin D3 through exposure to UVB light.

Vitamin D is created in our bodies after skin’s exposure to UVB light, but the major source is food. This new biofortified crop could help millions of people with vitamin D insufficiency, a growing issue linked to higher risk of cancer, dementia, and many leading causes of mortality. Studies have also shown that vitamin D insufficiency is linked to increased severity of infection by Covid-19.

Scientists have long known that touching plants can set off a stress reaction in them – but until now it hasn’t been exactly clear how that worked at a molecular level, something that a new study hopes to shed light on.

The researchers behind the study have identified certain genetic keys inside plants that lead to two separate signaling pathways, explaining why plants react so strongly to being touched.

Understanding more about how this process works at a fundamental level could help researchers in a variety of different areas, from improving plant health to getting higher harvest yields from the same crop.

Summary: Researchers have designed a new method of converting non-neural cells into functioning neurons that are able to form synapses, dispense dopamine, and restore the function of neurons undermined by Parkinson’s associated destruction of dopaminergic cells.

Neurodegenerative diseases damage and destroy neurons, ravaging both mental and physical health. Parkinson’s disease, which affects over 10 million people worldwide, is no exception. The most obvious symptoms of Parkinson’s disease arise after the illness damages a specific class of neuron located in the midbrain. The effect is to rob the brain of dopamine—a key neurotransmitter produced by the affected neurons.

In new research, Jeffrey Kordower and his colleagues describe a process for converting non-neuronal cells into functioning neurons able to take up residence in the brain, send out their fibrous branches across neural tissue, form synapses, dispense dopamine and restore capacities undermined by Parkinson’s destruction of dopaminergic cells.

Researchers at Meta’s Artificial Intelligence Research Lab (Facebook) in the U.S. and at the University of Twente’s Neuromechanical Modelling and Engineering Lab in the Netherlands (led by Prof.dr.ir Massimo Sartori), have co-developed the open-source framework MyoSuite, which combines advanced musculoskeletal models with advanced artificial intelligence (AI). The AI-powered digital models in MyoSuite can learn to execute complex movements and interactions with assistive robots, that would otherwise require long experimentations on real human subjects.

Modeling and simulation are now as important to human health technologies as they have been for the advancement of modern automotive industry. Prof. Massimo Sartori: “If we could predict the outcome of a robotic therapy beforehand, then we could optimize it for a patient and deliver a truly personalized and cost-effective treatment.”

MyoSuite supports the co-simulation of AI-powered musculoskeletal systems physically interacting with assistive robots such as exoskeletons. With MyoSuite you can simulate biological phenomena, e.g., muscle fatigue, muscle sarcopenia, tendon tear and tendon reaffirmation. Moreover, you can simulate how assistive robots could be designed and controlled to restore movement following impairment.

Artificial intelligence (AI) is spreading through society into some of the most important sectors of people’s lives – from health care and legal services to agriculture and transportation.¹ As Americans watch this proliferation, they are worried in some ways and excited in others.

In broad strokes, a larger share of Americans say they are “more concerned than excited” by the increased use of AI in daily life than say the opposite. Nearly half of U.S. adults (45%) say they are equally concerned and excited. Asked to explain in their own words what concerns them most about AI, some of those who are more concerned than excited cite their worries about potential loss of jobs, privacy considerations and the prospect that AI’s ascent might surpass human skills – and others say it will lead to a loss of human connection, be misused or be relied on too much.

But others are “more excited than concerned,” and they mention such things as the societal improvements they hope will emerge, the time savings and efficiencies AI can bring to daily life and the ways in which AI systems might be helpful and safer at work. And people have mixed views on whether three specific AI applications are good or bad for society at large.